Singapore to subsidise genetic testing for some conditions as part of precision medicine programme

Key Concepts

• Subsidized Genetic Testing: Government-funded genetic tests to make them more accessible.
• National Precision Medicine Program: A national initiative to leverage genetic information for personalized healthcare.
• Preventive Action: Taking steps to avoid or mitigate potential health issues.
• Clinically and Cost-Effective: Tests that are proven to be medically beneficial and economically viable.
• High LDL Cholesterol (Bad Cholesterol): A type of cholesterol that significantly increases the risk of heart disease.
• Hereditary Breast and Ovarian Cancer: Cancers linked to specific genetic mutations that can be inherited.
• Genome Sequencing: Determining the complete DNA sequence of an organism.
• Health Span: The period of life spent in good health.
• Insurance Underwriting: The process insurance companies use to assess risk and determine premiums.

Subsidized Genetic Testing for Preventive Healthcare

The Ministry of Health (MOH) in Singapore is introducing subsidized genetic testing for certain conditions to encourage residents to take proactive steps for their health without the barrier of cost. Health Minister Ong Ye Kung announced this initiative at the launch of Phase 3 of the National Precision Medicine program.

Rationale for Genetic Testing

Unlike medical imaging like MRIs and CT scans, which provide a snapshot of health at a specific moment, genetic information is permanent. A one-time genetic test has the potential to predict future illnesses a person might develop throughout their lifetime. This capability is seen as a crucial tool for Singaporeans to access preventive care and early treatment.

Eligibility for Subsidies and Downstream Interventions

Minister Ong stated that genetic tests, once proven to be clinically and cost-effective, will be categorized as a distinct type of test. Those with defined use cases will receive subsidies. This will also make them eligible for "downstream interventions," which are subsequent medical actions or treatments that result from the test findings. These interventions, such as stroke prevention treatments and intensified surveillance, will also be supported.

Initial Use Cases and Expansion Plans

1. High LDL Cholesterol:

• The first identified use case for subsidized testing is for individuals with very high LDL cholesterol, commonly known as "bad cholesterol."
• High LDL cholesterol significantly elevates the risk of heart disease, even in younger individuals.
• Since June, over 200 people have consented to have their genes tested for this condition.

2. Hereditary Breast and Ovarian Cancer:

• Singapore is planning to expand this program to include hereditary breast and ovarian cancer.
• This expansion is based on ongoing genome sequencing of the Singaporean population.

National Precision Medicine Program: Phase 3

The National Precision Medicine program has entered its third phase, with the ambitious goal of sequencing the DNA of half a million people in Singapore. This large-scale genomic data collection aims to identify conditions that are particularly prevalent in the population and for which early intervention can improve "health span" (the period of life spent in good health).

Identifying Cost-Effective Interventions

The program prioritizes interventions that are not only effective in improving health span but also cost-effective. Minister Ong highlighted that while the initial focus was on high LDL cholesterol, hereditary breast and ovarian cancer is considered another strong candidate that fits these criteria.

Legal Safeguards for Genetic Test Results

To foster public trust in precision medicine, the MOH is working on new legislation. These laws will ensure that genetic test results cannot be used for insurance underwriting or by employers. This measure aims to protect individuals' privacy and prevent potential discrimination based on their genetic predispositions.